- Home
- Blog
- News
- Basics
- Sources
- Agencies, Regulatory & Organisations
- CERSI Excipients Browser
- Excipient Report
- Excipient DMF List
- EXCiPACT Certified Companies
- Excipient Documentation
- Excipient EINECS Numbers
- Excipient E-Numbers
- FDA Inactive Ingredient List
- FDA GRAS Substances (SCOGS) Database
- IPEC Americas
- USP - U.S. Pharmacopeia
- Definitions
- Whitepapers / Publications
- Supplier
- Services
- Media
- Events
- 1st pharmaexcipients Poster Award
- Event Calendar
- Events featured by pharma-excipients
- 4th Annual Formulation & Drug Delivery Congress
- DDF Summit
- ExcipientFest Americas
- ExcipientFest Asia
- Global CompliancePanel
- International Conference and Exhibition on Pharmaceutics & Novel Drug Delivery Systems
- Formulation & Drug Delivery USA Congress
- Laboratory Medicine 2018
- Making Pharmaceuticals Europe
- Making Pharmaceuticals Exhibition
- Pharma Integrates
- PharmaExcipients China @CPhI China
- TTC Technology Training Center
- Jobs
- Online Sourcing
- Contact
07. October 2017
Burst drug release is often considered a negative phenomenon resulting in unexpected toxicity or tissue irritation. Optimal release of a highly soluble active pharmaceutical ingredient (API) from hypromellose (HPMC) matrices is technologically impossible; therefore, a combination of polymers is required for burst effect reduction. Promising variant could be seen in combination of HPMC and insoluble Eudragits® as water dispersions. These can be applied only on API/insoluble filler mixture as...
20. February 2017
Abstract Adsorption of lipid-based formulations, which are usually liquid, onto silicas has been extensively investigated in the past decade to convert them into solid dosage forms. There are conflicting reports on the ability of commercially available porous silicas, like Neusilin® US2, to release lipid formulations completely, especially after long-term storage. In this study, the release of a model drug, probucol, from different formulations of medium chain lipids and a surfactant,...
27. December 2016
ABSTRACT For pharmaceutical tablet prodution, there are lots of commercial excipients available. All these excipients influence the drug release of tablet cores in different ways. In this project the influence of Carbopol 71G®, Carbopol 971P®, Fujicalin®, Neusilin US2®, Neusilin UFL2®, Pemulen TR-1®, Pemulen TR-2®, Sepistab ST 200® and Sepitrap 80® on drug release was investigated. Tablets were compressed with resveratrol as a model drug using an eccentric press. Tablets containing 2...
09. August 2016
ABSTRACT For pharmaceu cal tablet produc on, there are lots of commercial excipients available. All these excipients in uence the drug release of tablet cores in di erent ways. In this project the in uence of Carbopol 71G®, Carbopol 971P®, Fujicalin®, Neusilin US2®, Neusilin UFL2®, Pemulen TR-1®, Pemulen TR-2®, Sepistab ST 200® and Sepitrap 80® on drug release was inves gated. Tablets were compressed with resveratrol as a model drug using an eccentric press. Tablets containing 2 wt.%...